A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BG’s primer for Busy Clinicians.
Thank you @JCOOP_ASCO@EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
https://t.co/HJhZlsBpU2
Interested in the major trials in critical care?
We have summarised and critiqued 250 of the most important randomised controlled trials stretching back over the past 25 years.
https://t.co/iKZvgQOLlu
📊 JAMA Clinical Guidelines Synopsis: The 2025 guideline for #ACS management recommends dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, high-intensity statins, invasive revascularization, and radial access for angiography.
https://t.co/cRfu42LO0s
Drug-induced liver injury (DILI) Consult demonstrates the potential of LLMs to assist clinicians in evaluating DILI. OPEN ACCESS: https://t.co/0LmADfWR6l
Today's Paper of the Day is:
Traumatic pneumothorax and hemothorax: What you need to know
https://t.co/JKgcYjlUQ5
Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2026
Have you reviewed the 2025 update on the ACLS guidelines? If not, no worries! AEMP has you covered. This week's #PulseDose clinical pearl is on the 2025 ACLS guidelines! 🚑️ 🚨
#AEMP#AEMPlify#EMRx#ACLS
🔥Just published🔥
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 : Critical Care Medicine #IDXposts https://t.co/jRP9hZFI8W
Thanks for having me on to talk about the role & evolution of EM pharmacy. I'm grateful for the chance to thoughtfully debate & elevate our profession on @emcrit! Also got to shout out @SAEM_AEMP
If you don't have an EM pharmacist, give this a listen to find out why you should!
When optimally dosed, these β-lactams achieve comparable outcomes with favorable safety profiles and antimicrobial stewardship advantages. https://t.co/VVRHUtqzJu
See the results of the COBRRA Trial!
Bleeding risk increased with Rivaroxaban vs Apixaban.
What do you think about these results? Will this impact your practice?
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism | NEJM https://t.co/FQDAPDfQOX
Improve your geriatric emergency care - from anywhere! Register for our FREE virtual education Geriatric Emergency Medicine Symposium. Visit https://t.co/TbNtGsRFgY for more info and to register today!
The fear of linezolid-induced serotonin syndrome is often overblown!
🆕💫Single-center, retrospective, single-cohort study , N: 227 patient
LZD 🚫 Serotonergic agent
Only 2 patients were identified with possible serotonin toxicity as defined by the Sternbach or Hunter criteria, with one case possibly associated with linezolid https://t.co/OMeQIUcFh3
❄️ Winter is coming… and so are the pneumonia admits.
CURB-65, PSI/PORT, SMART-COP.
One guides admit vs discharge, another predicts mortality, and one spots who’s about to crash
New on @REBEL_EM 👉 https://t.co/rNQ1FFXGNE
#FOAMed#EM#Pneumonia#MedTwitter